PepGen Inc. reported second quarter 2026 financial results and clinical updates for its investigational therapy PGN-EDODM1, which targets myotonic dystrophy type 1 (DM1). The company held $117.2 million in cash as of June 30, 2026, sufficient to fund operations into the fourth quarter of 2027. For the quarter ended June 30, 2026, PepGen reported a net loss of $17.8 million, or $(0.26) per share, compared to a net loss of $23.1 million in the prior year period. Research and development expenses decreased to $12.5 million from $18.4 million, while general and administrative expenses rose to $6.4 million from $5.5 million. Clinically, an independent Data and Safety Monitoring Board recommended advancing the Phase 2 FREEDOM2-DM1 study into the highest dose cohort of 12.5 mg/kg and escalating doses in the open-label extension study from 5 mg/kg to 10 mg/kg based on favorable safety data. PepGen Inc. is a clinical-stage biotechnology company developing oligonucleotide therapies for severe neuromuscular and neurological diseases.